What is Zacks Research’s Forecast for Bruker Q3 Earnings?

Bruker Corporation (NASDAQ:BRKR) – Stock analysts at Zacks Research decreased their Q3 2025 EPS estimates for shares of Bruker in a research report issued to clients and investors on Tuesday, October 21st. Zacks Research analyst Team now expects that the medical research company will post earnings per share of $0.33 for the quarter, down from their previous forecast of $0.37. The consensus estimate for Bruker’s current full-year earnings is $2.69 per share. Zacks Research also issued estimates for Bruker’s Q4 2025 earnings at $0.85 EPS, FY2025 earnings at $1.97 EPS, Q1 2026 earnings at $0.44 EPS, Q2 2026 earnings at $0.43 EPS, Q3 2026 earnings at $0.53 EPS, Q4 2026 earnings at $0.69 EPS, FY2026 earnings at $2.09 EPS, Q1 2027 earnings at $0.53 EPS, Q2 2027 earnings at $0.59 EPS and FY2027 earnings at $2.46 EPS.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Monday, August 4th. The medical research company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). Bruker had a net margin of 2.31% and a return on equity of 17.89%. The firm had revenue of $797.40 million during the quarter, compared to the consensus estimate of $811.17 million. During the same period in the previous year, the business earned $0.52 earnings per share. The firm’s revenue for the quarter was down .4% on a year-over-year basis. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS.

Several other brokerages also recently commented on BRKR. Citigroup cut their price target on shares of Bruker from $40.00 to $38.00 and set a “neutral” rating for the company in a report on Monday, August 4th. Wells Fargo & Company dropped their price objective on shares of Bruker from $60.00 to $50.00 and set an “overweight” rating for the company in a report on Tuesday, August 5th. Bank of America dropped their price objective on shares of Bruker from $61.00 to $50.00 and set a “buy” rating for the company in a report on Thursday, June 26th. Jefferies Financial Group set a $60.00 price objective on shares of Bruker and gave the stock a “buy” rating in a report on Monday, August 4th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Bruker in a report on Wednesday, October 8th. Five analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $51.00.

Bruker Stock Up 1.8%

Shares of NASDAQ:BRKR opened at $38.78 on Wednesday. The firm has a fifty day moving average price of $33.76 and a two-hundred day moving average price of $37.00. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.61 and a quick ratio of 0.70. Bruker has a one year low of $28.53 and a one year high of $64.64. The company has a market cap of $5.88 billion, a price-to-earnings ratio of 74.58, a PEG ratio of 5.33 and a beta of 1.20.

Bruker Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, October 3rd. Shareholders of record on Tuesday, September 23rd were paid a $0.05 dividend. The ex-dividend date of this dividend was Tuesday, September 23rd. This represents a $0.20 annualized dividend and a yield of 0.5%. Bruker’s payout ratio is currently 38.46%.

Insiders Place Their Bets

In other Bruker news, Director Cynthia M. Friend sold 3,535 shares of the business’s stock in a transaction on Friday, September 12th. The shares were sold at an average price of $32.25, for a total value of $114,003.75. Following the completion of the sale, the director directly owned 18,016 shares of the company’s stock, valued at $581,016. The trade was a 16.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 27.30% of the stock is owned by corporate insiders.

Institutional Trading of Bruker

Hedge funds have recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC lifted its stake in Bruker by 377.5% in the second quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company’s stock worth $25,000 after purchasing an additional 487 shares during the last quarter. Pinnacle Bancorp Inc. purchased a new position in shares of Bruker in the first quarter valued at about $29,000. Huntington National Bank increased its position in shares of Bruker by 750.0% in the second quarter. Huntington National Bank now owns 731 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 645 shares during the period. Allworth Financial LP increased its position in shares of Bruker by 92.4% in the first quarter. Allworth Financial LP now owns 758 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 364 shares during the period. Finally, Spire Wealth Management purchased a new position in shares of Bruker in the second quarter valued at about $32,000. 79.52% of the stock is owned by institutional investors.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.